Join the club for FREE to access the whole archive and other member benefits.

Reason examines the failure of Unity Biotechnology's phase 2 senolytics trial

18-Aug-2020

Key points from article :

Senolytics selectively destroy a sizable fraction of the senescent cells that accumulate in old tissues.

UNITY announced the failure of a phase II study of UBX0101, a p53/MDM2 interaction inhibitor, for knee osteoarthritis.

No statistically significant difference change from baseline in WOMAC-A (measurement of pain in OA).

Study adopted a single dose localized injection approach for their delivery of senolytics.

Much lower amounts of the drug can be used - desirable when the drug is a toxic chemotherapeutic compound.

But not clear that the harm done by senescent cells is local to a significant enough degree.

Possible reasons for failure:

- small molecule drug used may just not work reliably enough in humans in comparison to mice

- local administration may be a poor strategy if the goal is to reduce inflammatory burden

- targetted mechanism may not be as useful as hoped

Numerous other groups are working on the problem, and most have what look to be better approaches.

Disappointing first result - but lessons learnt and plenty of other strategies available

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Academic

CEO of Repair Technologies and founder of Fight Aging

Company

Biotechnology company devoted to research of restoring human health